ALX Oncology to Present ALX148 Clinical Data at the 62nd American Society of Hematology (ASH) Annual Meeting
05 Novembre 2020 - 1:00PM
ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a
clinical-stage immuno-oncology company developing therapies to
block the CD47 checkpoint mechanism, today announced that both
ALX148 clinical and preclinical results have been selected for
presentation at the 62nd ASH Annual Meeting & Exposition,
December 5-8, 2020.
“This year’s ASH meeting will be an opportunity to provide
important clinical updates on our ALX148 program in patients with
hematologic malignancies,” said Sophia Randolph M.D., Ph.D., Chief
Medical Officer of ALX Oncology. “We are excited to share new
clinical efficacy data that investigates the combination of ALX148
with rituximab in patients with relapsed/refractory NHL. We are
committed to further development of ALX148 to transform standards
of care for patients with cancer.”
Poster
Presentation
Details
Title: ALX148, a CD47 Blocker, in
Combination with Rituximab in Patients with Non-Hodgkin
Lymphoma
Session Name: 626. Aggressive Lymphoma –
Results from Prospective Clinical Trials: Poster III
Presentation Date and
Location: December 7, 7:00am – 3:30pm PT,
Virtual Poster Hall
Publication Number: 3016
Abstract
Link:
https://ash.confex.com/ash/2020/webprogram/Paper135941.html
Title: ALX148 Enhances the Depth
and Durability of Response to Multiple AML Therapies
Session Name: 616. Acute Myeloid Leukemia:
Novel Therapy, excluding Transplantation: Poster II
Presentation Date and
Location: December 6, 7:00am – 3:30pm PT,
Virtual Poster Hall
Publication Number: 1965
Abstract
Link:
https://ash.confex.com/ash/2020/webprogram/Paper137112.html
About ALX OncologyALX Oncology is a
publicly traded, clinical-stage immuno-oncology company focused on
helping patients fight cancer by developing therapies that block
the CD47 checkpoint pathway and bridge the innate and adaptive
immune system. ALX Oncology’s lead product candidate, ALX148, is a
next generation CD47 blocking therapeutic that combines a
high-affinity CD47 binding domain with an inactivated, proprietary
Fc domain. ALX148 has demonstrated promising clinical responses
across a range of hematologic and solid malignancies in combination
with a number of leading anti-cancer agents. ALX Oncology intends
to continue clinical development of ALX148 for the treatment of a
range of solid tumor indications and myelodysplastic syndromes. For
more information, please visit ALX Oncology’s website
at www.alxoncology.com.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended. Such forward-looking statements are
based on ALX Oncology’s beliefs and assumptions and on information
currently available to it on the date of this press release.
Forward-looking statements may involve known and unknown risks,
uncertainties and other factors that may cause ALX Oncology’s
actual results, performance or achievements to be materially
different from those expressed or implied by the forward-looking
statements. These statements include but are not limited to
statements regarding ALX Oncology’s clinical pipeline and the
expectations regarding the beneficial characteristics, safety,
efficacy and therapeutic effects of ALX148. These and other risks
are described more fully in ALX Oncology’s filings with the
Securities and Exchange Commission (“SEC”), including ALX
Oncology’s Quarterly Report on Form 10-Q, filed with the SEC on
August 27, 2020, and other documents ALX Oncology subsequently
files with the SEC from time to time. Except to the extent required
by law, ALX Oncology undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
Investor Contact:
Peter Garcia
Chief Financial Officer, ALX Oncology
(650) 466-7125 Ext. 113
peter@alxoncology.com
Argot Partners
(212)-600-1902
alx@argotpartners.com
Media Contact:
Karen Sharma
MacDougall
(781) 235-3060
alx@macbiocom.com
Grafico Azioni ALX Oncology (NASDAQ:ALXO)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni ALX Oncology (NASDAQ:ALXO)
Storico
Da Lug 2023 a Lug 2024